Stifel Financial’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-45,665
| Closed | -$691K | – | 3429 |
|
|
2022
Q3 | $691K | Sell |
45,665
-143,361
| -76% | -$1.67M | ﹤0.01% | 2222 |
|
|
2022
Q2 | $1.42M | Buy |
189,026
+5,012
| +3% | +$35.3K | ﹤0.01% | 1740 |
|
|
2022
Q1 | $1.68M | Buy |
184,014
+53,904
| +41% | +$415K | ﹤0.01% | 1744 |
|
|
2021
Q4 | $913K | Buy |
130,110
+27,984
| +27% | +$293K | ﹤0.01% | 2194 |
|
|
2021
Q3 | $1.16M | Buy |
102,126
+20,587
| +25% | +$301K | ﹤0.01% | 1972 |
|
|
2021
Q2 | $1.3M | Sell |
81,539
-3,840
| -4% | -$65.9K | ﹤0.01% | 1894 |
|
|
2021
Q1 | $1.53M | Sell |
85,379
-10,115
| -11% | -$175K | ﹤0.01% | 1692 |
|
|
2020
Q4 | $1.29M | Sell |
95,494
-62,236
| -39% | -$752K | ﹤0.01% | 1666 |
|
|
2020
Q3 | $1.86M | Buy |
157,730
+58,427
| +59% | +$712K | ﹤0.01% | 1252 |
|
|
2020
Q2 | $1.47M | Buy |
99,303
+13,416
| +16% | +$198K | ﹤0.01% | 1326 |
|
|
2020
Q1 | $1.16M | Sell |
85,887
-42,369
| -33% | -$804K | ﹤0.01% | 1342 |
|
|
2019
Q4 | $3.08M | Sell |
128,256
-21,987
| -15% | -$455K | 0.01% | 1086 |
|
|
2019
Q3 | $2.89M | Buy |
150,243
+47,265
| +46% | +$1.08M | 0.01% | 1072 |
|
|
2019
Q2 | $3.04M | Buy |
102,978
+7,522
| +8% | +$290K | 0.01% | 1074 |
|
|
2019
Q1 | $4.55M | Buy |
95,456
+8,620
| +10% | +$379K | 0.01% | 851 |
|
|
2018
Q4 | $3.15M | Buy |
86,836
+2,956
| +4% | +$139K | 0.01% | 959 |
|
|
2018
Q3 | $5.15M | Buy |
83,880
+5,615
| +7% | +$361K | 0.01% | 831 |
|
|
2018
Q2 | $5.29M | Buy |
78,265
+1,089
| +1% | +$60.9K | 0.02% | 789 |
|
|
2018
Q1 | $4.18M | Sell |
77,176
-8,282
| -10% | -$463K | 0.01% | 863 |
|
|
2017
Q4 | $5.1M | Buy |
85,458
+621
| +0.7% | +$37.7K | 0.02% | 754 |
|
|
2017
Q3 | $4.12M | Buy |
84,837
+1,655
| +2% | +$90.3K | 0.01% | 812 |
|
|
2017
Q2 | $4.38M | Sell |
83,182
-4,419
| -5% | -$206K | 0.02% | 773 |
|
|
2017
Q1 | $3.97M | Sell |
87,601
-5,950
| -6% | -$265K | 0.02% | 799 |
|
|
2016
Q4 | $3.55M | Sell |
93,551
-1,306
| -1% | -$49.4K | 0.02% | 793 |
|
|
2016
Q3 | $3.59M | Sell |
94,857
-17,931
| -16% | -$395K | 0.02% | 757 |
|
|
2016
Q2 | $1.99M | Sell |
112,788
-14,020
| -11% | -$227K | 0.01% | 1006 |
|
|
2016
Q1 | $1.54M | Buy |
126,808
+31,170
| +33% | +$493K | 0.01% | 1041 |
|
|
2015
Q4 | $2.33M | Buy |
95,638
+5,355
| +6% | +$125K | 0.01% | 892 |
|
|
2015
Q3 | $1.6M | Sell |
90,283
-37,673
| -29% | -$682K | 0.01% | 1017 |
|
|
2015
Q2 | $2.26M | Sell |
127,956
-43,213
| -25% | -$792K | 0.01% | 930 |
|
|
2015
Q1 | $5.36M | Sell |
171,169
-320,993
| -65% | -$9.3M | 0.03% | 595 |
|
|
2014
Q4 | $20.9M | Buy |
492,162
+296,595
| +152% | +$7.52M | 0.12% | 219 |
|
|
2014
Q3 | $4.05M | Buy |
+195,567
| New | +$3.86M | 0.04% | 536 |
|
Stifel Financial's AERI Position: Q4 2022 in Review
Stifel Financial sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 45,665 shares — an estimated $691K sold.
Stifel Financial first reported a position in AERI in Q3 2014 and held it in 33 quarters. The position peaked at $20.9M in Q4 2014. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Stifel Financial reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Stifel Financial sold 45,665 Aerie Pharmaceuticals shares in Q4 2022, an estimated $691K.
- Stifel Financial first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 33 quarters.
- Stifel Financial's Aerie Pharmaceuticals position peaked at $20.9M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Stifel Financial's 13F filing for Q4 2022, filed 13 Feb 2023.